NCT06605300 - The Effects of Oxytocin and Vasopressin on Delta-beta Cross-frequency Coupling | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

July 28, 2025

Study Completion Date

August 12, 2025

Conditions

Healthy

Interventions

DRUG

Intranasal Oxytocin (IN-OXT)

Subject assigned to receive intranasal administration of oxytocin (24 IU).

DRUG

Intranasal Vasopressin (AVP)

Subjects assigned to receive intranasal administration of vasopressin (20 IU).

DRUG

Intranasal Placebo

Subjects assigned to receive intranasal administration of placebo.

Trial Locations (2)

University of Electronic Science and Technology of China, Chengdu

University of Electronic Science and Technology of China (UESTC), Chengdu

All Listed Sponsors

lead

University of Electronic Science and Technology of China

OTHER